The National Cancer Institute Selects Integral Molecular, Inc. to Map Epitopes on Cancer Biomarkers using Shotgun Mutagenesis Mapping Technology
10/1/2009 9:24:36 AM
PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, Inc. has been selected by the National Cancer Institute (NCI) to map epitopes for monoclonal antibodies directed against cancer biomarkers. Protein targets of interest to the Clinical Cancer Proteomics community will be analyzed using Shotgun Mutagenesis Mapping technology to identify amino acids that are essential for antibody binding, allowing the discovery and characterization of cancer-specific biomarkers. The $150,000 contract will be fully funded by the NCI.